William Ho

Company: IN8Bio
Job title: CEO
Seminars:
Sharing Results of Allogeneic Gamma Delta Therapy in AML Patients 4:00 pm
Discussing the rationale for developing chemo-resistant gamma delta therapy and clinical trial design as an adjuvant with current standard-of-care Choosing indications based on medical need and biological features of gamma delta T cells Presenting clinical results from phase 1 studies, highlighting efficacy and toxicity dataRead more
day: Day One